CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 22511Orig1s000

PHARMACOLOGY REVIEW(S)



MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

FROM: Sushanta Chakder, Ph.D., Supervisory Pharmacologist

DATE: April 13, 2010

Application number: NDA 22,511

Date of submission: June 30, 2009

Sponsor: POZEN Pharmaceutical Development Co.

Drug Product: VIMOVO (Naproxen/Esomeprazole magnesium)

Indication: Treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients at risk of developing NSAID-associated gastric ulcer

Comments:

Under NDA 22511, the sponsor is seeking approval of a combination of naproxen and esomeprazole magnesium for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients at risk of developing NSAID-associated gastric ulcer. The only nonclinical study submitted in this NDA application was a pharmacokinetic study in which the urinary and plasma metabolites of buffered and unbuffered omeprazole were determined in female Sprague Dawley rats following 14 days of oral dosing. The NDA was supported by reference to the Agency's previous findings of safety and publicly available information on the toxicology of naproxen and esomeprazole (including omeprazole) to meet the nonclinical assessment requirements.

The nonclinical safety of esomeprazole and naproxen has been established by the respective innovators. During approval of the espmeprazole (Nexium) application, its nonclinical safety was partially based on studies conducted with omeprazole. Following oral administration of omeprazole buffered and unbuffered formulation to female Sprague Dawley rats, the plasma and urinary metabolite profiles for omeprazole were similar. Thus, following oral administration of uncoated esomeprazole, present in VIMOVO, the patients are not expected to be exposed to any new metabolites. Since the mechanisms of action, and the microsomal enzyme systems involved in the metabolism the two components of VIMOVO are not similar, no significant drug-drug interactions between the two components are expected. The sponsor adopted the labeling of the nonclinical sections from the existing labeling of the individual components which is acceptable.

Recommendations:

1. I concur with Dr. Wu's recommendation that there are no additional nonclinical safety concerns for the proposed combination of naproxen and esomeprazole, other than those expected from the individual components.




2. In the nonclinical sections of the labeling (Sections 8.1 and 13.1), the sponsor used
headings for reproductive toxicology and carcinogenicity studies of individual
components of VIMOVO. These headings should be removed form the labeling.

3. From a nonclinical standpoint	, the NDA	application	is approvable	with the
recommended changes in the lab	eling.			

Sushanta Chakder, Ph. D. Date Supervisory Pharmacologist, HDF-180



Application Type/Number	Submission Type/Number	Submitter Name	Product Name					
NDA-22511	ORIG-1	POZEN INC	PN 400 NAPROXEN/ESOMEPRAZOLE MAGNESIUM					
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.								
/s/								
SUSHANTA K CH 04/13/2010	IAKDER							



DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION

Application number: 22511

Supporting document/s: 1

Applicant's letter date: June 30, 2009

CDER stamp date: July 1, 2009

Product: VIMOVO (naproxen/esomeprazole magnesium)

Indication: Treatment of osteoarthritis, rheumatoid arthritis

and ankylosing spondylitis patients at risk for

developing NSAID-associated gastric ulcer

Applicant: POZEN Pharmaceutical Development Co.

Review Division: Gastroenterology Products

Reviewer: Charles G. Wu. Ph.D.

Supervisor/Team Leader: Sushanta Chakder, Ph.D.

Division Director: Donna Griebel, M.D.

Project Manager: Anna Simon, MSN, CPNP

Disclaimer

Except as specifically identified, all data and information discussed below and necessary for approval of NDA 22511 are owned by POZEN Pharmaceutical Co. or are data for which POZEN Pharmaceutical Co. has obtained a written right of reference. Any information or data necessary for approval of NDA 22511 that POZEN Pharmaceutical Co. does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as described in the drug's approved labeling. Any data or information described or referenced below from a previously approved application that POZEN Pharmaceutical Co. does not own (or from FDA reviews or summaries of a previously approved application) is for descriptive purposes only and is not relied upon for approval of NDA 22511.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

